FLT3 and acute myeloid leukemia: In AML, most often, these FLT3 mutations are internal tandem duplications (ITD) or missense mutations in the tyrosine kinase domain (TKD), resulting in constitutive activation of the FLT3 kinase and activation of the RAS/MAPK pathway [82,83,84,85].